Market Research Report
Cancer Anorexia-Cachexia Syndrome - Pipeline Review, H2 2019
|Published by||Global Markets Direct||Product code||484626|
|Published||Content info||109 Pages
Delivery time: 1-2 business days
|Cancer Anorexia-Cachexia Syndrome - Pipeline Review, H2 2019|
|Published: November 18, 2019||Content info: 109 Pages||
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cancer Anorexia-Cachexia Syndrome - Pipeline Review, H2 2019, provides an overview of the Cancer Anorexia-Cachexia Syndrome (Oncology) pipeline landscape.
Cancer anorexia-cachexia syndrome is defined as progressive weight loss associated with malignancy and is characterized by loss of appetite (anorexia), skeletal muscle wasting, and reduced adipose tissue. Approximately 50% of cancer patients report abnormalities of eating behavior at the time of first diagnosis and prevalence is even higher at approximately 65%. The incidence of weight loss upon diagnosis varies greatly according to the tumor site.
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Cancer Anorexia-Cachexia Syndrome - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Cancer Anorexia-Cachexia Syndrome (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Cancer Anorexia-Cachexia Syndrome (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Cancer Anorexia-Cachexia Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 4, 14 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 3 molecules, respectively.
Cancer Anorexia-Cachexia Syndrome (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.